Lead Product(s) : GT-2108
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Palisade Bio
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Palisade wil develop, manufacture and commercialize Giiant’s proprietary targeted prodrug platform, including GT-2108, an orally administered, gut-restricted, colon-specific PDE4 inhibitor prodrug in development for patients affect...
Product Name : GT-2108
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 09, 2023
Lead Product(s) : GT-2108
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Palisade Bio
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Avenanthramide
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Avenanthramides provide relief from a host of skin conditions, such as eczema, allergic rash, chicken pox and insect bites. Ceapro is the only commercial manufacturer of commercially available avenanthramides extracted and purified from oats.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 22, 2022
Lead Product(s) : Avenanthramide
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AUR200
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AUR200 is a recombinant Fc fusion protein designed to specifically BAFF and APRIL. BAFF and APRIL promote B cell survival and differentiation and have been shown to play a prominent role in the pathogenesis of certain autoimmune and nephrology conditions...
Product Name : AUR200
Product Type : Protein
Upfront Cash : Inapplicable
September 20, 2022
Lead Product(s) : AUR200
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palmitoylethanolamide
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FSD Pharma holds exclusive worldwide (excluding Italy and Spain) licensing rights to FSD-201 for all conditions in all regulatory categories. FSD-201 (Palmitoylethanolamide) is a proprietary formulation of ultra-micronized palmitoylethanolamide (PEA).
Product Name : FSD201
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 31, 2022
Lead Product(s) : Palmitoylethanolamide
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mescaline
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biomind Labs to Commence Commercial Clinical Trial on Its Proprietary Mescaline Candidate BMND06
Details : BMND06, (a novel formulation based on the psychedelic molecule mescaline), is naturally occurring psychedelic compound, binding and activating, the serotonin 5-HT2A receptor with high affinity, for treating a wide range of therapeutic indications.
Product Name : BMND06
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 24, 2022
Lead Product(s) : Mescaline
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GT-2108
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Amplitude Ventures
Deal Size : $1.2 million
Deal Type : Financing
Details : Giiant Pharma already initiated its IND-enabling preclinical program with its lead candidate, GT-2108, for the treatment of moderate-to-severe ulcerative colitis. This additional financing will support the development of GT-2108 up to clinical Phase 1b c...
Product Name : GT-2108
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 30, 2021
Lead Product(s) : GT-2108
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Amplitude Ventures
Deal Size : $1.2 million
Deal Type : Financing
Lead Product(s) : GT-2108
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Amplitude Ventures
Deal Size : $11.0 million
Deal Type : Financing
Giiant Pharma inc Announced the Closing of US$11M in Seed Financing
Details : The Company has identified GT-2108 as a lead candidate for the treatment of inflammatory bowel diseases (IBD). GT-2108 is an orally-administered, colon-specific PDE4 inhibitor prodrug with potent anti-inflammatory properties.
Product Name : GT-2108
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 19, 2021
Lead Product(s) : GT-2108
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Amplitude Ventures
Deal Size : $11.0 million
Deal Type : Financing
Lead Product(s) : Cannabidiol
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Revive is currently in the process of preparing its Investigational New Drug (“IND”) application for submission to the U.S. Food and Drug Administration (“FDA”) for CBD in the treatment of AIH.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 18, 2020
Lead Product(s) : Cannabidiol
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable